Core Viewpoint - The announcement details the achievement of the second vesting condition for the restricted stock incentive plan of Guangzhou Maipu Medical Technology Co., Ltd, indicating that the conditions for vesting have been met for 41 eligible participants, allowing for the allocation of 437,691 shares [14][22]. Summary by Sections Incentive Plan Overview - The 2023 restricted stock incentive plan involves granting 1,868,000 shares, representing approximately 2.83% of the company's total share capital as of the plan's announcement date [2]. - The first grant consists of 1,768,000 shares (2.68% of total capital), while 100,000 shares are reserved for future grants (0.15% of total capital) [2]. Grant and Vesting Conditions - The vesting period for the first grant starts 12 months after the grant date and lasts up to 60 months, with specific performance conditions tied to company revenue growth [3][4]. - The vesting schedule includes three phases: 30% after 12 months, 30% after 24 months, and 40% after 36 months from the grant date [5][6]. Performance Assessment - The performance targets for the incentive plan are based on annual revenue growth rates, with specific thresholds set for each year from 2023 to 2025 [8][17]. - The company must achieve a minimum revenue growth of 12% in the first year, 36% in the second year, and 72% in the third year to meet the vesting conditions [8][18]. Approval and Compliance - The plan has undergone necessary approvals from the board and supervisory committee, confirming that all conditions for the second vesting period have been met [10][22]. - Legal opinions affirm that the plan complies with relevant laws and regulations, ensuring no harm to the interests of the company or its shareholders [21][22]. Shareholder Impact - The total number of shares available for vesting represents 0.66% of the company's total share capital, reflecting the company's commitment to aligning employee incentives with shareholder interests [20][22]. - The adjusted grant price for the restricted stock is set at 19.80 RMB per share, following previous adjustments due to corporate actions [19][22].
迈普医学: 关于2023年限制性股票激励计划首次授予部分第二个归属期归属条件成就的公告